01—Abstract
Summary
Summary of the 8-K filed June 23, 2025. Cited figures are marked; the original filing is the authoritative source.
On June 22, 2025, Illumina, Inc. entered into a Stock Purchase Agreement with Standard BioTools Inc. to acquire SomaLogic, Inc., Sengenics Corporation LLC, and Sengenics Corporation Pte Ltd, along with Standard BioTools' aptamer-based and functional proteomics business (including KREX, Single SOMAmer, translational and diagnostic assays).
The business excludes Standard BioTools' mass cytometry and microfluidics businesses. Illumina will pay $350,000,000a in cash at closing, subject to customary adjustments, plus royalty streams and up to $75,000,000 in potential milestone payments tied to revenues from certain products and services. The closing is subject to customary conditions, including expiration or termination of the Hart-Scott-Rodino waiting period, absence of enjoining orders, and absence of a material adverse effect with respect to the Group Companies or the Business.
The agreement can be terminated if closing has not occurred by March 23, 2026, subject to three automatic three-month extensions for certain regulatory clearances. Illumina would owe Standard BioTools a $14,500,000b termination fee if the agreement is terminated under specified regulatory-clearance failure circumstances. Ancillary agreements include a transition services agreement and a license agreement under which Illumina grants Standard BioTools a non-transferable, non-sublicensable license to certain Illumina intellectual property.
In the accompanying press release, Illumina states that SomaLogic brings an aptamer-based affinity proteomics platform into its portfolio, that the kitted NGS-based panels business will add a high-margin consumables revenue stream, and that the business is expected to become profitable in 2027 on a non-GAAP operating income basis. Illumina expects to close the transaction in the first half of 2026. The companies have partnered on proteomics co-development since December 2021, and Illumina Protein Prep will become available to all customers starting in the third quarter of 2025.
02—Key points
Key Highlights
- Illumina agreed to acquire SomaLogic and related Standard BioTools aptamer-based and functional proteomics assets for $350,000,000 in cash at closing, subject to customary adjustments.
- Up to $75,000,000 in potential milestone payments to Standard BioTools, plus royalty streams tied to revenues from certain products and services.
- Closing is subject to HSR Act waiting period expiration or termination, absence of enjoining orders, and absence of a material adverse effect; the press release expects closing in the first half of 2026.
- Outside date is March 23, 2026, with three automatic three-month extensions for certain regulatory clearances.
- Illumina would pay a $14,500,000 termination fee if the agreement terminates under specified regulatory-clearance failure circumstances.
- The acquisition includes SomaLogic's Boulder, Colorado facilities and approximately 250 employees, per the press release.
- Illumina expects the kitted NGS-based panels business to become profitable in 2027 on a non-GAAP operating income basis, with margins in line with Illumina in 2028.
03—Questions
Frequently Asked Questions
What is Illumina acquiring and for how much?
Illumina is acquiring SomaLogic, Inc., Sengenics Corporation LLC, and Sengenics Corporation Pte Ltd, plus Standard BioTools' aptamer-based and functional proteomics business, for $350,000,000 in cash at closing, subject to customary adjustments, plus up to $75,000,000 in potential milestone payments and royalties.
What is excluded from the transaction?
The business excludes Standard BioTools' mass cytometry and microfluidics businesses.
When is the deal expected to close, and what could delay it?
Illumina expects closing in the first half of 2026. Closing depends on HSR Act waiting period expiration or termination, any other required approvals, the absence of enjoining laws or orders, and the absence of a material adverse effect, among other customary conditions. The agreement's outside date is March 23, 2026, subject to three automatic three-month extensions for certain regulatory clearances.
What happens if the deal fails on regulatory grounds?
If the agreement is terminated under specified circumstances relating to failure to obtain certain regulatory clearances, Illumina would be required to pay Standard BioTools a termination fee of $14,500,000.
What does the transaction mean for Illumina's proteomics strategy?
Per the press release, the acquisition brings SomaLogic's aptamer-based affinity proteomics platform into Illumina's portfolio, builds on a co-development agreement begun in December 2021, and is intended to bring proteomics onto Illumina's NGS platforms, advancing its multiomics strategy. Illumina Protein Prep will become available to all customers starting in the third quarter of 2025.
04—Continue